On December 28th, 2021 the FDA authorized, for the first time, outpatient use of COVID-19 convalescent plasma. The announcement letter can be found here. 

As COVID-19 surges in the United States and around the world, we want to reiterate the following statements:

•  Sign the petitions:
  • Newest Open letter to NIH commenting on CCP recommendations made 12/2/22. Sign here.
  • Open letter to NIH for revisions to CCP recommendations.  The NIH Research Committee letter with the first signatories can be found here. The petition can be found here. 
  • Open letter to WHO for revisions to CCP recommendations. The WHO letter with the first signatories can be found here. The petition can be found here.
• Convalescent plasma remains under EUA in the United States.
• Convalescent plasma is more effective when used early in treatment, research highlighting this can be found here and here. 
• Local convalescent plasma is preferable to distantly sourced convalescent plasma.
• The COMPILE statistics team (members of the Division of Biostatistics at the Department of Population Health, and New York University Grossman School of Medicine) built a COVID-19 Convalescent Plasma treatment index tool to guide treatment decisions. The tool can be found in the Health Care Providers section of this website.